Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Paul Chapman, Martin Madaus

Premium

Quanterix has named Paul Chapman as its new president and CEO. In the latter role, Chapman replaces Martin Madaus who will remain as executive chairman of the privately held firm's board of directors.

In his new roles, Chapman will oversee the commercialization of Quanterix's Simoa technology (see related story, this issue). He joins Quanterix from EMD Millipore, where he was vice president of its BioPharm Process Solutions business. Prior to joining Millipore, he was vice president of hospital solutions for Roche Near Patient Testing in Austria. Chapman was also the international business development manager at Roche Molecular Diagnostics for blood screening and held a number of sales and marketing positions at Roche Diagnostics Canada, where he began his career in 1993.

Chapman holds a BSc in microbiology from the University of Western Ontario, a BSc in immunology from the University of Guelph in Ontario, and graduated from the marketing management program at the Richard Ivy School of Business in London, Ontario.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.